Endpoints News

Lilly partners again with Innovent		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

Mon T W Th F

9 February, 2026

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

presented by

7 Real-World Ways RWE Is Transforming Healthcare

news

Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages

•

US calls for investigation of Hims over GLP-1 drugs, threatening 'decisive steps'

•

Hims says it will stop selling GLP-1 pill, after legal pressure from US

Lilly returns to Innovent to partner on cancer and immune diseases

A confluence of factors contributed to Sanofi's Phase 3 multiple sclerosis trial fail

CGT has fresh momentum from new FDA frameworks and pharma deals, but do the latest advances in science, manufacturing, and regulation actually solve the core challenges? We’re asking the hard questions — join us.

endpoints pharma

TrumpRx launches with few drugs, many with generic competitors available

HHS drops legal fight over blocked 340B rebate pilot, says it may consider new version

Orphan drug tweak in US spending bill will make life easier for the FDA

in case you missed it

Agomab, SpyGlass cap biggest week for biotech IPOs since 2021

Peer Review

Geoff McDonough's big plans for NodThera's NLRP3; Enhertu leader steps down at Daiichi

Biogen CEO expects Alzheimer's drug Leqembi to sustain growth

News Briefing

UniQure pauses higher doses in Fabry study; Aro shares Pompe data

Roivant spinout heads to Phase 3 with ‘landmark’ data in immune skin disease

Illumina bets on healthcare customers after NIH funding disruptions

‘I thought we’d be faster and I was wrong’: Sanofi chief defends R&D pivot

In a stunning turn of events, Hims on Saturday said it has canceled plans to sell a compounded version of Novo’s Wegovy pill after it riled up the pharma industry and the US government. This morning, the Danish drugmaker is taking more decisive action, announcing it is suing Hims for alleged patent infringement. Read the latest here.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com